A citation-based method for searching scientific literature

Gary Kohanbash, Diego A Carrera, Shruti Shrivastav, Brian J Ahn, Naznin Jahan, Tali Mazor, Zinal S Chheda, Kira M Downey, Payal B Watchmaker, Casey Beppler, Rolf Warta, Nduka A Amankulor, Christel Herold-Mende, Joseph F Costello, Hideho Okada. J Clin Invest 2017
Times Cited: 158



Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick, Kathryn E Wellen, Donald M O'Rourke, Shelley L Berger, Timothy A Chan, Ross L Levine, Ingo K Mellinghoff, Craig B Thompson. Nature 2012
Times Cited: 1183




List of shared articles



Times cited


Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Julie Leca, Jerome Fortin, Tak W Mak. Curr Opin Biotechnol 2021
3

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.
Elia Aguado-Fraile, Ania Tassinari, Yuko Ishii, Carlie Sigel, Maeve A Lowery, Lipika Goyal, Camelia Gliser, Liewen Jiang, Shuchi S Pandya, Bin Wu,[...]. Future Oncol 2021
2

The Roles of 2-Hydroxyglutarate.
Xin Du, Hai Hu. Front Cell Dev Biol 2021
2

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes. Mol Diagn Ther 2021
1

The implications of IDH mutations for cancer development and therapy.
Christopher J Pirozzi, Hai Yan. Nat Rev Clin Oncol 2021
1

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Maria B Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen Carney, Brandon McClellan, Kaushik Banerjee, Mahmoud S Alghamri, Faisal Syed, Padma Kadiyala, Felipe J Nunez,[...]. Front Oncol 2021
0

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Alisan Kayabolen, Ebru Yilmaz, Tugba Bagci-Onder. Biomedicines 2021
0

Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers.
Kun Yao, Hua Liu, Jiajun Yin, Jianmin Yuan, Hong Tao. J Exp Clin Cancer Res 2021
0

Oligodendroglioma: A Review of Management and Pathways.
Maroun Bou Zerdan, Hazem I Assi. Front Mol Neurosci 2021
0

2-Hydroxyglutarate in Cancer Cells.
Petr Ježek. Antioxid Redox Signal 2020
23

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
Sue Han, Yang Liu, Sabrina J Cai, Mingyu Qian, Jianyi Ding, Mioara Larion, Mark R Gilbert, Chunzhang Yang. Br J Cancer 2020
50

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020
44

Lower Grade Gliomas.
Gilbert Youssef, Julie J Miller. Curr Neurol Neurosci Rep 2020
5

Metabolite sensing and signaling in cancer.
Yi-Ping Wang, Jin-Tao Li, Jia Qu, Miao Yin, Qun-Ying Lei. J Biol Chem 2020
4

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Yang Liu, Fengchao Lang, Fu-Ju Chou, Kareem A Zaghloul, Chunzhang Yang. Biomedicines 2020
13

Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.
Narges Zare Mehrjardi, Daniel Hänggi, Ulf Dietrich Kahlert. Cell Death Dis 2020
9

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Sara Verdura, Elisabet Cuyàs, Jesús Lozano-Sánchez, Cristian Bastidas-Velez, Laura Llorach-Parés, Salvador Fernández-Arroyo, Anna Hernández-Aguilera, Jorge Joven, Alfons Nonell-Canals, Joaquim Bosch-Barrera,[...]. Carcinogenesis 2019
8